Radiology Medical News about NSCLC

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Combination of radiotherapy and chemotherapy in locally advanced NSCLC
Expert Review of Anticancer Therapy, 10/20/09

Kepka L et al. – The combination of radiotherapy and chemotherapy is considered to be a standard approach for patients with locally advanced, stage III non–small–cell lung cancer. The current state of the art of combined radiochemotherapy supported by evidence–based data is presented. The new methods to improve treatment results, such as selection of proper strategies, incorporation of molecular agents into combined treatment and radiotherapy technique modifications are discussed.

<< Previous
Interventional Endoscopic Ultrasound: The Next Frontier in...

Next >>
Radiochemotherapy in small-cell lung cancer

Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related Non-Small Cell Lung Cancer Through Aberrant Methylation and Alterations of EGFR Signaling
Annals of Surgical Oncology, 10/23/09 Relevance Score: 89%

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09 Relevance Score: 87%

Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
Journal of Clinical Oncology, 10/29/09 Relevance Score: 85%

Expression and Significance of Clusterin in Anip973/CDDP Cell Lines
Chinese Journal of Lung Cancer, 10/23/09 Relevance Score: 85%

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09 Relevance Score: 85%